Is XGN or FLGT more profitable?

Fulgent Genetics has a net margin of -26.05% compared to Exagen's net margin of -26.61%. Fulgent Genetics' return on equity of -4.93% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% Fulgent Genetics -26.05% -4.93% -4.50%

Is XGN or GMRS more profitable?

GMR Solutions has a net margin of 0.00% compared to Exagen's net margin of -26.61%. GMR Solutions' return on equity of 0.00% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% GMR Solutions N/A N/A N/A

Which has better valuation and earnings, SBC or XGN?

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SBC Medical Group $173.61M 3.16 $50.99M $0.47 11.36 Exagen $66.57M 3.02 -$19.95M -$0.81 N/A

Is SBC or XGN more profitable?

SBC Medical Group has a net margin of 27.99% compared to Exagen's net margin of -26.61%. SBC Medical Group's return on equity of 18.47% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets SBC Medical Group 27.99% 18.47% 13.10% Exagen -26.61% -104.46% -28.93%

Which has preferable earnings & valuation, VMD or XGN?

Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viemed Healthcare $270.28M 1.32 $14.93M $0.36 26.03 Exagen $66.57M 3.02 -$19.95M -$0.81 N/A

Is VMD or XGN more profitable?

Viemed Healthcare has a net margin of 4.81% compared to Exagen's net margin of -26.61%. Viemed Healthcare's return on equity of 10.16% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Viemed Healthcare 4.81% 10.16% 7.22% Exagen -26.61% -104.46% -28.93%

Exagen (XGN) Competitors

$8.30 +0.11 (+1.34%)

Closing price 10/7/2026 04:00 PM Eastern

Extended Trading

$8.30 0.00 (0.00%)

As of 10/7/2026 07:58 PM Eastern

Compare

XGN vs. FLGT, GMRS, SBC, SRTA, and VMD

Should you buy Exagen stock or one of its competitors? Exagen's main competitors and comparable companies include Fulgent Genetics (FLGT), GMR Solutions (GMRS), SBC Medical Group (SBC), Strata Critical Medical (SRTA), and Viemed Healthcare (VMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Exagen compare to Fulgent Genetics?

Exagen (NASDAQ:XGN) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Fulgent Genetics had 3 more articles in the media than Exagen. MarketBeat recorded 3 mentions for Fulgent Genetics and 0 mentions for Exagen. Exagen's average media sentiment score of 1.22 beat Fulgent Genetics' score of 0.51 indicating that Exagen is being referred to more favorably in the media.

Company	Overall Sentiment
Exagen	Positive
Fulgent Genetics	Positive

Exagen has a beta of 2.12, suggesting that its share price is 112% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Exagen currently has a consensus target price of $9.63, suggesting a potential upside of 15.96%. Fulgent Genetics has a consensus target price of $27.50, suggesting a potential upside of 33.69%. Given Fulgent Genetics' higher possible upside, analysts plainly believe Fulgent Genetics is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

75.3% of Exagen shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 10.4% of Exagen shares are held by insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Exagen has higher earnings, but lower revenue than Fulgent Genetics. Exagen is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	3.02	-$19.95M	-$0.81	N/A
Fulgent Genetics	$322.67M	1.75	-$60.51M	-$2.82	N/A

Fulgent Genetics has a net margin of -26.05% compared to Exagen's net margin of -26.61%. Fulgent Genetics' return on equity of -4.93% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

Summary

Exagen beats Fulgent Genetics on 9 of the 17 factors compared between the two stocks.

How does Exagen compare to GMR Solutions?

Exagen (NASDAQ:XGN) and GMR Solutions (NYSE:GMRS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

GMR Solutions has lower revenue, but higher earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than GMR Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	3.02	-$19.95M	-$0.81	N/A
GMR Solutions	N/A	N/A	N/A	-$1.56	N/A

GMR Solutions has a net margin of 0.00% compared to Exagen's net margin of -26.61%. GMR Solutions' return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
GMR Solutions	N/A	N/A	N/A

75.3% of Exagen shares are owned by institutional investors. 10.4% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, GMR Solutions had 2 more articles in the media than Exagen. MarketBeat recorded 2 mentions for GMR Solutions and 0 mentions for Exagen. Exagen's average media sentiment score of 1.22 beat GMR Solutions' score of 0.44 indicating that Exagen is being referred to more favorably in the media.

Company	Overall Sentiment
Exagen	Positive
GMR Solutions	Neutral

Exagen currently has a consensus price target of $9.63, indicating a potential upside of 15.96%. GMR Solutions has a consensus price target of $18.78, indicating a potential upside of 85.19%. Given GMR Solutions' higher possible upside, analysts plainly believe GMR Solutions is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
GMR Solutions	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

Summary

Exagen beats GMR Solutions on 7 of the 13 factors compared between the two stocks.

How does Exagen compare to SBC Medical Group?

SBC Medical Group (NASDAQ:SBC) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SBC Medical Group	$173.61M	3.16	$50.99M	$0.47	11.36
Exagen	$66.57M	3.02	-$19.95M	-$0.81	N/A

SBC Medical Group presently has a consensus price target of $8.50, suggesting a potential upside of 59.18%. Exagen has a consensus price target of $9.63, suggesting a potential upside of 15.96%. Given SBC Medical Group's higher probable upside, equities analysts plainly believe SBC Medical Group is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SBC Medical Group	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

SBC Medical Group has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Exagen has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market.

60.8% of SBC Medical Group shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 81.7% of SBC Medical Group shares are held by insiders. Comparatively, 10.4% of Exagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

SBC Medical Group has a net margin of 27.99% compared to Exagen's net margin of -26.61%. SBC Medical Group's return on equity of 18.47% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SBC Medical Group	27.99%	18.47%	13.10%
Exagen	-26.61%	-104.46%	-28.93%

In the previous week, SBC Medical Group had 3 more articles in the media than Exagen. MarketBeat recorded 3 mentions for SBC Medical Group and 0 mentions for Exagen. Exagen's average media sentiment score of 1.22 beat SBC Medical Group's score of 0.54 indicating that Exagen is being referred to more favorably in the news media.

Company	Overall Sentiment
SBC Medical Group	Positive
Exagen	Positive

Summary

SBC Medical Group beats Exagen on 11 of the 17 factors compared between the two stocks.

How does Exagen compare to Strata Critical Medical?

Exagen (NASDAQ:XGN) and Strata Critical Medical (NASDAQ:SRTA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

75.3% of Exagen shares are held by institutional investors. Comparatively, 47.4% of Strata Critical Medical shares are held by institutional investors. 10.4% of Exagen shares are held by insiders. Comparatively, 15.5% of Strata Critical Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Exagen currently has a consensus target price of $9.63, indicating a potential upside of 15.96%. Strata Critical Medical has a consensus target price of $8.00, indicating a potential upside of 70.94%. Given Strata Critical Medical's higher probable upside, analysts plainly believe Strata Critical Medical is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Strata Critical Medical	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75

Strata Critical Medical has higher revenue and earnings than Exagen. Strata Critical Medical is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	3.02	-$19.95M	-$0.81	N/A
Strata Critical Medical	$197.14M	2.10	$41.35M	-$0.04	N/A

Exagen has a beta of 2.12, suggesting that its share price is 112% more volatile than the broader market. Comparatively, Strata Critical Medical has a beta of 2.43, suggesting that its share price is 143% more volatile than the broader market.

In the previous week, Exagen's average media sentiment score of 1.22 beat Strata Critical Medical's score of 0.00 indicating that Exagen is being referred to more favorably in the media.

Company	Overall Sentiment
Exagen	Positive
Strata Critical Medical	Neutral

Strata Critical Medical has a net margin of 15.71% compared to Exagen's net margin of -26.61%. Strata Critical Medical's return on equity of -2.97% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
Strata Critical Medical	15.71%	-2.97%	-2.54%

Summary

Strata Critical Medical beats Exagen on 9 of the 15 factors compared between the two stocks.

How does Exagen compare to Viemed Healthcare?

Viemed Healthcare (NASDAQ:VMD) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viemed Healthcare	$270.28M	1.32	$14.93M	$0.36	26.03
Exagen	$66.57M	3.02	-$19.95M	-$0.81	N/A

Viemed Healthcare has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Exagen has a beta of 2.12, suggesting that its share price is 112% more volatile than the broader market.

In the previous week, Viemed Healthcare had 1 more articles in the media than Exagen. MarketBeat recorded 1 mentions for Viemed Healthcare and 0 mentions for Exagen. Exagen's average media sentiment score of 1.22 beat Viemed Healthcare's score of 0.92 indicating that Exagen is being referred to more favorably in the news media.

Company	Overall Sentiment
Viemed Healthcare	Positive
Exagen	Positive

74.2% of Viemed Healthcare shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 20.6% of Viemed Healthcare shares are held by company insiders. Comparatively, 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Viemed Healthcare has a net margin of 4.81% compared to Exagen's net margin of -26.61%. Viemed Healthcare's return on equity of 10.16% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viemed Healthcare	4.81%	10.16%	7.22%
Exagen	-26.61%	-104.46%	-28.93%

Viemed Healthcare presently has a consensus target price of $14.00, indicating a potential upside of 49.41%. Exagen has a consensus target price of $9.63, indicating a potential upside of 15.96%. Given Viemed Healthcare's higher probable upside, analysts plainly believe Viemed Healthcare is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viemed Healthcare	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Viemed Healthcare beats Exagen on 10 of the 17 factors compared between the two stocks.

Get Exagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XGN vs. The Competition

Export

Metric	Exagen	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$198.41M	$9.80B	$7.16B	$13.44B
Dividend Yield	N/A	2.61%	2.53%	16.47%
P/E Ratio	-10.25	33.71	274.55	26.10
Price / Sales	3.02	4.84	581.05	87.31
Price / Cash	N/A	119.03	77.41	52.81
Price / Book	10.78	5.11	10.73	6.27
Net Income	-$19.95M	$315.68M	$3.50B	$382.03M
7 Day Performance	2.09%	-1.49%	-1.54%	-0.89%
1 Month Performance	9.50%	-4.05%	-6.72%	-5.31%
1 Year Performance	-24.27%	8.51%	5.74%	0.76%

Exagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XGN Exagen	3.4872 of 5 stars	$8.30 +1.3%	$9.63 +16.0%	-24.3%	$198.41M	$66.57M	N/A	220	Positive News Gap Down
FLGT Fulgent Genetics	3.0285 of 5 stars	$21.50 +1.0%	$27.50 +27.9%	-9.1%	$590.92M	$322.67M	N/A	1,315	Positive News
GMRS GMR Solutions	4.4527 of 5 stars	$9.75 +3.5%	$18.78 +92.6%	N/A	$526.70M	N/A	N/A	34,000
SBC SBC Medical Group	3.9914 of 5 stars	$5.06 -0.2%	$8.50 +68.0%	+29.6%	$519.91M	$173.61M	10.76	863	Analyst Upgrade
SRTA Strata Critical Medical	1.9321 of 5 stars	$4.78 -1.1%	$8.00 +67.5%	N/A	$422.44M	$197.14M	N/A	601

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XGN) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exagen (XGN) Competitors

XGN vs. FLGT, GMRS, SBC, SRTA, and VMD

How does Exagen compare to Fulgent Genetics?

Summary

How does Exagen compare to GMR Solutions?

Summary

How does Exagen compare to SBC Medical Group?

Summary

How does Exagen compare to Strata Critical Medical?

Summary

How does Exagen compare to Viemed Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exagen (XGN) Competitors

XGN vs. FLGT, GMRS, SBC, SRTA, and VMD

How does Exagen compare to Fulgent Genetics?

Does the media refer more to XGN or FLGT?

Which has more risk and volatility, XGN or FLGT?

Do analysts recommend XGN or FLGT?

Do insiders and institutionals hold more shares of XGN or FLGT?

Which has higher earnings & valuation, XGN or FLGT?

Is XGN or FLGT more profitable?

Summary

How does Exagen compare to GMR Solutions?

Which has higher earnings and valuation, XGN or GMRS?

Is XGN or GMRS more profitable?

Do institutionals & insiders believe in XGN or GMRS?

Does the media prefer XGN or GMRS?

Do analysts recommend XGN or GMRS?

Summary

How does Exagen compare to SBC Medical Group?

Which has better valuation and earnings, SBC or XGN?

Do analysts rate SBC or XGN?

Which has more volatility and risk, SBC or XGN?

Do insiders and institutionals have more ownership in SBC or XGN?

Is SBC or XGN more profitable?

Does the media favor SBC or XGN?

Summary

How does Exagen compare to Strata Critical Medical?

Do institutionals & insiders believe in XGN or SRTA?

Do analysts prefer XGN or SRTA?

Which has higher valuation and earnings, XGN or SRTA?

Which has more risk and volatility, XGN or SRTA?

Does the media refer more to XGN or SRTA?

Is XGN or SRTA more profitable?

Summary

How does Exagen compare to Viemed Healthcare?

Which has preferable earnings & valuation, VMD or XGN?

Which has more volatility and risk, VMD or XGN?

Does the media prefer VMD or XGN?

Do insiders and institutionals believe in VMD or XGN?

Is VMD or XGN more profitable?

Do analysts rate VMD or XGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools